April 22nd 2025
With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics production, gene therapy capabilities, and next generation R&D centers.
Protecting Public Health: Lorna Meldrum, Seqirus
September 28th 2021Lorna Meldrum, Vice President, Commercial Operations, International Markets & Pandemic at Seqirus, talks about the challenges of the influenza vaccine market and how COVID-19 has highlighted that preventing ’flu is crucial for public health.
Setting Sights on the COVID Vaccine Market: Shankar Musunuri, CEO, Ocugen
September 27th 2021Dr. Shankar Musunuri talks about his 25 years’ experience in biotech about his company Ocugen’s latest mission to develop, manufacture, and commercialize Bharat Biotech’s COVID-19 vaccine, COVAXIN, in the North American market.
Physician Practices Post-Pandemic: Q&A with Jenny Sherak, AmerisourceBergen
July 6th 2021Jenny Sherak, SVP & President of Specialty Physician Services at AmerisourceBergen, talks about how the needs of physician practices have evolved during the COVID-19 pandemic and what is required to navigate the shifting healthcare landscape.